Cancer Therapeutics CRC, Wellcome Trust, Merck, Cancer Research UK deal

Cancer Research UK’s commercialization and development arm, Cancer Research Technology (CRT), granted Merck worldwide rights to develop and commercialize inhibitors of protein arginine methyltransferase 5 (PRMT5). The inhibitors were developed by Cancer Therapeutics CRC (CTx) with support from CRT and the Wellcome Trust.

Merck is responsible for development and commercialization of the PRMT5 inhibitors and is funding a research collaboration with CTx focused on blood disorders. ...